- Home
- DRS vs EXEL Comparison
DRS vs EXEL Comparison
Compare DRS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRS
- EXEL
- Stock Information
- Founded
- DRS 1969
- EXEL 1994
- Country
- DRS United States
- EXEL United States
- Employees
- DRS N/A
- EXEL 1147
- Industry
- DRS Military/Government/Technical
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DRS Industrials
- EXEL Health Care
- Exchange
- DRS Nasdaq
- EXEL Nasdaq
- Market Cap
- DRS 9.7B
- EXEL 11.1B
- IPO Year
- DRS N/A
- EXEL 2000
- Fundamental
- Price
- DRS $35.46
- EXEL $43.09
- Analyst Decision
- DRS Strong Buy
- EXEL Buy
- Analyst Count
- DRS 6
- EXEL 24
- Target Price
- DRS $46.83
- EXEL $44.73
- AVG Volume (30 Days)
- DRS 1.5M
- EXEL 3.2M
- Earning Date
- DRS 10-29-2025
- EXEL 11-04-2025
- Dividend Yield
- DRS 1.01%
- EXEL N/A
- EPS Growth
- DRS 33.93
- EXEL 53.55
- EPS
- DRS 0.99
- EXEL 2.38
- Revenue
- DRS $3,569,000,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- DRS $12.03
- EXEL $9.14
- Revenue Next Year
- DRS $6.76
- EXEL $12.51
- P/E Ratio
- DRS $35.97
- EXEL $18.08
- Revenue Growth
- DRS 12.27
- EXEL 9.93
- 52 Week Low
- DRS $28.17
- EXEL $31.90
- 52 Week High
- DRS $49.31
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- DRS 28.98
- EXEL 66.44
- Support Level
- DRS $34.50
- EXEL $39.83
- Resistance Level
- DRS $35.97
- EXEL $43.22
- Average True Range (ATR)
- DRS 1.07
- EXEL 1.36
- MACD
- DRS -0.18
- EXEL 0.50
- Stochastic Oscillator
- DRS 12.79
- EXEL 96.68
About DRS Leonardo DRS Inc.
Leonardo DRS Inc is a provider of defense products and technologies that are used across land, air, sea, space, and cyber domains. The company is in the design, development, and manufacture of Advanced sensing, network computing, force protection, and electric power and propulsion technologies and solutions. The company has two segments: Advanced Sensing and Computing, which generates the majority of revenue, and the Integrated Mission Systems segment. The Advanced Sensing and Computing segment is engaged in designing, developing, and manufacturing sensing and network computing technology that enables real-time situational awareness required for enhanced operational decision-making and execution by the customers.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.